15.06.2021 • News

Indorama Developing US Oxides R&D Center

The Integrated Oxides & Derivatives (IOD) business of Indorama Ventures (IVL), Thailand-based global petrochemical producer best known as the world’s largest producer of PET resin, is developing a new technology center at The Woodlands, Texas.

The new facility will be the company’s US research and development hub for new products used in a variety of applications, including home, personal and industrial cleaning, agrochemicals, energy, lubricants, mining and coatings.

Indorama acquired the IOD business activity from US chemical producer Huntsman at the beginning of 2020, and it is now one of the company’s three global segments, in addition to Fibers and Combined PET. Alastair Port, the segment’s president and COO, said the facility will be a “significant milestone on IVL’s ‘future ready’ roadmap” and will serve as a center of excellence for the development of new niche and sustainability product lines.

Extensive design and engineering of the research center will start in the coming months, the company said, with full occupation expected in early 2022. The premises are planned to be a hub for IOD research in the Americas, with links to sister facilities in Australia, India, and China.

The Woodlands unit will also support IVL’s Fibers and PET segments on various sustainability projects. The company, which bills itself as the world’s largest manufacturer of fully recyclable PET bottles, is currently investing $1.5 billion toward meeting its recycling and net zero emissions targets.

Author: Dede Williams, Freelance Journalist

Thailand-based global petrochemical producer and world’s largest manufacturer...
Thailand-based global petrochemical producer and world’s largest manufacturer of PET resin, Indorama Ventures, (IVL), is developing a new US research hub for new products used in a variety of applications at The Woodlands, Texas. Operation is to start in 2022. (c) pixabay

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read